Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iCorrelate: 89Zr-Df-IAB22M2C PET Tracer in Solid Tumors
NCT03802123Phase 2Completed
- Sponsor
- ImaginAb
- Start
- Dec 2018
- Primary completion
- Oct 2021
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of zirconium-89 crefmirlimab berdoxam in melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), squamous cell carcinoma of the head and neck (HNSCC), sponsored by ImaginAb. Started Dec 2018; status: completed.
02
Drugs
zirconium-89 crefmirlimab berdoxam
03
Conditions
melanomanon-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03802123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03802123.